These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 17638694)

  • 1. In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1.
    Dandache S; Sévigny G; Yelle J; Stranix BR; Parkin N; Schapiro JM; Wainberg MA; Wu JJ
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4036-43. PubMed ID: 17638694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
    Koh Y; Das D; Leschenko S; Nakata H; Ogata-Aoki H; Amano M; Nakayama M; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2009 Mar; 53(3):997-1006. PubMed ID: 18955518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PL-100, a novel HIV-1 protease inhibitor displaying a high genetic barrier to resistance: an in vitro selection study.
    Dandache S; Coburn CA; Oliveira M; Allison TJ; Holloway MK; Wu JJ; Stranix BR; Panchal C; Wainberg MA; Vacca JP
    J Med Virol; 2008 Dec; 80(12):2053-63. PubMed ID: 19040279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antiviral activity of the novel, tyrosyl-based human immunodeficiency virus (HIV) type 1 protease inhibitor brecanavir (GW640385) in combination with other antiretrovirals and against a panel of protease inhibitor-resistant HIV.
    Hazen R; Harvey R; Ferris R; Craig C; Yates P; Griffin P; Miller J; Kaldor I; Ray J; Samano V; Furfine E; Spaltenstein A; Hale M; Tung R; St Clair M; Hanlon M; Boone L
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3147-54. PubMed ID: 17620375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates.
    De Meyer S; Azijn H; Surleraux D; Jochmans D; Tahri A; Pauwels R; Wigerinck P; de Béthune MP
    Antimicrob Agents Chemother; 2005 Jun; 49(6):2314-21. PubMed ID: 15917527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and structural evaluation of PL-100 as a potential second-generation HIV-1 protease inhibitor.
    Asahchop EL; Oliveira M; Quashie PK; Moisi D; Martinez-Cajas JL; Brenner BG; Tremblay CL; Wainberg MA
    J Antimicrob Chemother; 2013 Jan; 68(1):105-12. PubMed ID: 22945918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue culture drug resistance analysis of a novel HIV-1 protease inhibitor termed PL-100 in non-B HIV-1 subtypes.
    Asahchop EL; Oliveira M; Brenner BG; Martinez-Cajas JL; Toni Td; Ntemgwa M; Moisi D; Dandache S; Stranix B; Tremblay CL; Wainberg MA
    Antiviral Res; 2010 Sep; 87(3):367-72. PubMed ID: 20541566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral activity and cross-resistance profile of P-1946, a novel human immunodeficiency virus type 1 protease inhibitor.
    Sévigny G; Stranix B; Tian B; Dubois A; Sauvé G; Petropoulos C; Lie Y; Hellmann N; Conway B; Yelle J
    Antiviral Res; 2006 Jun; 70(2):17-20. PubMed ID: 16473417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir.
    Dam E; Lebel-Binay S; Rochas S; Thibaut L; Faudon JL; Thomas CM; Essioux L; Hill A; Schutz M; Clavel F
    Antivir Ther; 2007; 12(3):371-80. PubMed ID: 17591027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
    Cunyat F; Ruiz L; Marfil S; Puig T; Bofill M; Blanco J; Clotet B; Cabrera C
    Antivir Ther; 2010; 15(3):431-6. PubMed ID: 20516562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Modified P1 Moiety Enhances In Vitro Antiviral Activity against Various Multidrug-Resistant HIV-1 Variants and In Vitro Central Nervous System Penetration Properties of a Novel Nonpeptidic Protease Inhibitor, GRL-10413.
    Amano M; Salcedo-Gómez PM; Zhao R; Yedidi RS; Das D; Bulut H; Delino NS; Sheri VR; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7046-7059. PubMed ID: 27620483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors.
    Yanchunas J; Langley DR; Tao L; Rose RE; Friborg J; Colonno RJ; Doyle ML
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3825-32. PubMed ID: 16127059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GRL-0519, a novel oxatricyclic ligand-containing nonpeptidic HIV-1 protease inhibitor (PI), potently suppresses replication of a wide spectrum of multi-PI-resistant HIV-1 variants in vitro.
    Amano M; Tojo Y; Salcedo-Gómez PM; Campbell JR; Das D; Aoki M; Xu CX; Rao KV; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2013 May; 57(5):2036-46. PubMed ID: 23403426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
    Koh Y; Nakata H; Maeda K; Ogata H; Bilcer G; Devasamudram T; Kincaid JF; Boross P; Wang YF; Tie Y; Volarath P; Gaddis L; Harrison RW; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2003 Oct; 47(10):3123-9. PubMed ID: 14506019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy.
    Rodés B; Sheldon J; Toro C; Jiménez V; Alvarez MA; Soriano V
    J Antimicrob Chemother; 2006 Apr; 57(4):709-13. PubMed ID: 16464891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.
    Aoki M; Venzon DJ; Koh Y; Aoki-Ogata H; Miyakawa T; Yoshimura K; Maeda K; Mitsuya H
    J Virol; 2009 Apr; 83(7):3059-68. PubMed ID: 19176623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A contribution to the drug resistance mechanism of darunavir, amprenavir, indinavir, and saquinavir complexes with HIV-1 protease due to flap mutation I50V: a systematic MM-PBSA and thermodynamic integration study.
    Leonis G; Steinbrecher T; Papadopoulos MG
    J Chem Inf Model; 2013 Aug; 53(8):2141-53. PubMed ID: 23834142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
    Weinheimer S; Discotto L; Friborg J; Yang H; Colonno R
    Antimicrob Agents Chemother; 2005 Sep; 49(9):3816-24. PubMed ID: 16127058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.